Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.
Doi H, Matsuo Y, Kishi N, Ogura M, Mitsuyoshi T, Ueki N, Ueki K, Fujii K, Sakamoto M, Atsuta T, Katagiri T, Sakamoto T, Narabayashi M, Ohtsu S, Fujishiro S, Kishi T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG).
Doi H, et al.
Target Oncol. 2024 Nov 7. doi: 10.1007/s11523-024-01105-5. Online ahead of print.
Target Oncol. 2024.
PMID: 39511126